anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to aplastic anemia controlling tablets, which are current novel products specially used for treating aplastic anemia. Aplastic anemia is a disease caused by gradually exhausted or partially stagnated bone marrow hematopoietic function. Aplastic anemia has a main clinical manifestation of pancytopenia. There are many causes for the disease, and heat-toxin is one of the causes. The tablets are prepared from 8 Chinese herbal medicines such as honeysuckle flower, forsythia suspense and Tokyo violet herb. The tablets provide functions of heat clearing, detoxifying, blood cooling, swelling subsiding, and warm pathogen dispelling. The tablets provide substantial treatment effects for aplastic anemia patients.
An exercise program will be performed to increase range of motion, improve motor learning and strengthen the muscles of the lower limb. The program will include exercises 2 times a week for four weeks. The first week the exercises will be performed with 2 sets of 15 repetitions and the remaining weeks 3 sets of 15 repetitions for each exercise. To exercise will be performed with the resistance of cinnamon, It will be recommended weight by 70% of one repetition maximum painless assigned individually per patient.
Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to 2-3 capillary glycemic tests per day.
The present invention discloses a wrist- or forearm-mounted device for dispensing a small amount of alcohol-based disinfectant hand rub, moisturizer, or other hand medicament. Even powder-based hand treatments can be dispensed using the present invention. A wristband or other attachment means affix the device to arm or wrist. Various locations are feasible including the top, side, or underside of the wrist or forearm. In a preferred embodiment, the device is in the form of the device is in the form of a wrist-mounted dispenser with a nozzle that uses refill cartridges or packets to supply a small amount of dispensed skin treatment when actuated. Surreptitious actuation and dispensing of hand treatments is made possible with embodiments of the invention that are mounted on the underside of the wrist and can be easily actuated in a casual, not easily detected manner.
PROBLEM TO BE SOLVED: To prepare a therapeutic agent for dermatopathy, comprising a lactic acid bacterial cell and capable of sustainedly suppressing pruritic dermatopathy caused by the proliferation of fungi such as a candida in an alimentary canal. SOLUTION: This therapeutic agent for dermatopathy comprises one or more of lactic acid bacterial belonging to the genera Lactobacillus, Bifidobacterium, Pediococcus, Streptococcus, Enterococcus and Leuconostoc and their treated substances as active ingredients. Since the lactic acid bacteria are used for foods or a strain separated from feces of a healthy human, the bacteria have no dangerousness of causing adverse effects. A heat-treated bacterial cell is preferably used. The bacterial cell can suitably be blended with a usually used additive and prepared as a tablet or a granule according to a conventional method. The daily dose of the agent used is 1×10<-9> to 5×10<12> cells/adult expressed in terms of the daily amount of the bacterial cell and the active ingredients.  The therapeutic agent is effective against palmoplantar putulosis, eczema nummulare, secondary eruption, erythema multiforme, chronic urticaria, atopic dermatitis, etc.
PURPOSE: Cardiac myxomas (CMs) are the second most common benign primary cardiac tumors, mainly originating within the left atrium. Approximately 5% of CM cases are associated with Carney Complex (CNC), an autosomal dominant multiple neoplasia syndrome often caused by germline mutations in the protein kinase A regulatory subunit 1A (PRKAR1A). Data concerning PRKAR1A alterations in sporadic myxomas are variable and sparse, with PRKAR1A mutations reported to range from 0% to 87%. Therefore, we investigated the frequency of PRKAR1A mutations in sporadic CM using next-generation sequencing (NGS). Additionally, we explored mutations in the catalytic domain of the Protein Kinase A complex (PRKACA) and examined the presence of GNAS mutations as another potential driver.
METHODS AND RESULTS: This study retrospectively collected histological and clinical data from 27 patients with CM. First, we ruled out the possibility of underlying CNC through clinical evaluations and standardized interviews for each patient. Second, we performed PRKAR1A immunohistochemistry (IHC) analysis and graded the reactivity of myxoma cells semi-quantitatively. NGS was then applied to analyze the coding regions of PRKAR1A, PRKACA, and GNAS in all 27 cases. Of the 27 sporadic CM cases, 13 (48%) harbored mutations in PRKAR1A. Among these 13 mutant cases, six displayed more than one mutation in PRKAR1A. Most of the identified mutations resulted in premature stop codons or affected splicing. In PRKAR1A mutant CM cases, the loss of PRKAR1A protein expression was significantly more common. In two cases with missense mutations, protein expression remained preserved. Furthermore, a single mutation was detected in the catalytic domain of the protein kinase A complex, while no GNAS mutations were found.
CONCLUSION: We identified a relatively high frequency of PRKAR1A mutations in sporadic CM. These PRKAR1A mutations may also represent an important oncogenic mechanism in sporadic myxomas, as already known in CM cases associated with CNC.
Placebo, matching T3D-959 active capsules, is pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects randomized to placebo will ingest three size 0 placebo capsules once per day in the morning.
The present invention relates generally to decellularized extracellular matrix of conditioned body tissues. The decellularized extracellular matrix contains a biological material, preferably vascular endothelial growth factor (VEGF), produced by the conditioned body tissue that is in an amount different than the amount of the biological material that the body tissue would produce absent the conditioning. The invention also relates to methods of making and methods of using said decellularized extracellular matrix. Specifically, the invention relates to treating defective, diseased, damaged or ischemic cells, tissues or organs in a subject by administering, injecting or implanting the decellularized extracellular matrix of the invention into a subject in need thereof. The invention is further directed to a tissue regeneration scaffold for implantation into a subject inflicted with a disease or condition that requires tissue or organ repair, regeneration and/or strengthening. Additionally, the invention is directed to a medical device, preferably a stent or an artificial heart, having a surface coated or covered with the decellularized extracellular matrix of the invention or having a component comprising the decellularized extracellular matrix of the invention for implantation into a subject, preferably a human. Methods for making the tissue regeneration scaffold and methods for manufacturing a coated or covered medical device having a component comprising decellularized extracellular matrix of conditioned body tissues are also provided.
A multi-site randomized controlled trial will be conducted to evaluate the effectiveness of two different types of group wellness interventions for partner caregivers of individuals with traumatic brain injury (TBI). 92 participants will be recruited. Participants are randomly assigned to one of two wellness groups. Each group will involve six weekly 75-minute live video conference sessions as well as independent homework assignments that will be discussed in closed social media forums with peers and facilitators. Participants will complete self-report measures (approach and avoidance, anxiety, depression, caregiver appraisal, resilience, self efficacy, social integration, quality of life.) prior to intervention participation, within a week of class 6, and at 3-months post-intervention.. Intervention effectiveness will be determined by improvements between baseline and follow-up on a self-report measure of approach/avoidance behaviors.
Hardenable two parts acrylic composition has been described. Described composition is included in the liquid Part I of stable storage and the liquid Part II of stable storage that while mixing, react each other the cement that forms sclerosis. Described composition also comprises acrylic monomer component and so that the initiator component of the amount of described monomer component polymerization. Described monomer component and described initiator component are usually located in the part of separating of described two parts composition so that described monomer component is stable storage. Described liquid Part I is included in the acrylic polymer particle of the emulsion polymerisation in liquid-carrier. A kind of method of producing hardenable two parts acrylic composition has also been described. Described composition have in the syringe of at least two cylinders or caulking gun particularly useful.
FIELD: medicine. ^ SUBSTANCE: inventions cover preparing the biologically active compounds of chlorine series -photosensitiser (PS) for photodynamic therapy (PDT). The PS contains chlorine e6 with N-methyl-D-glucamine and sodium in molar ratios as follows 1:2:1, and a cryostabiliser. The PS has structural formula (I): Also, th invention discloses the method for making the photosensitiser for photodynamic therapy according to which chlorine e6 is suspended in apyrogenic water; N-methyl-D-glucamine and sodium hydroxide (NaOH) are added in stirring. The prepared chlorine e6 salt solution is filtered with the cryostabiliser added in estimated amount, and lyophilised. ^ EFFECT: said PS shows prolonged storage-stability, improved service properties and the consumer appeal, extended storage life as a medical preparation. ^ 4 cl, 1 ex, 1 tbl
Inflammation and mucus production are prevalent characteristics of chronic respiratory conditions, such as asthma and chronic chronic obstructive pulmonary disease (COPD). Biological co-factors, including bacteria, viruses, and fungi, may exacerbate these diseases by activating various pathways associated with airway diseases. An example is the fungus Pneumocystis, which is linked to severe COPD in human patients. Recent evidence has demonstrated that Pneumocystis significantly enhanced inflammation and mucus hypersecretion in a rat model of elastase-induced COPD. The present study specifically aims to investigate two additional aspects associated with the pathology induced by Pneumocystis infection: inflammation and collagen deposition around airways. To this end, the focus was to investigate the role of the IL-1β pro-inflammatory pathway during Pneumocystis infection in COPD rats. Several airway pathology-related features, such as inflammation, mucus hypersecretion, and fibrosis, were evaluated using histological and molecular techniques. COPD animals infected with Pneumocystis exhibited elevated inflammation levels, including a synergistic increase in IL-1β and Cox-2. Furthermore, protein levels of the IL-1β-dependent transcription factor cAMP response element-binding (CREB) showed a synergistic elevation of their phosphorylated version in the lungs of COPD animals infected with Pneumocystis, while mucus levels were notably higher in the airways of COPD-infected animals. Interestingly, a CREB responsive element (CRE) was identified in the Muc5b promoter. The presence of CREB in the Muc5b promoter was synergistically increased in COPD animals infected with Pneumocystis compared to other experimental groups. Finally, an increment of deposited collagen was identified surrounding the airways of COPD animals infected with Pneumocystis compared with the other experimental animal groups and correlated with the increase of Tgfβ1 mRNA levels. These findings emphasize the role of Pneumocystis as a potential biological co-factor in chronic respiratory diseases like COPD or asthma, warranting new perspectives in the treatment of chronic respiratory diseases.
PURPOSE: A sustained release formulation using a gastric retention drug delivery system is provided to enable drugs to stay in the gastrointestinal tract for a long time and release the drugs continuously by adding a first controlled-release base and a second controlled-release base besides a swelling polymer. CONSTITUTION: A sustained release formulation using a gastric retention drug delivery system comprises: a pharmacological activity component, a swelling polymer, a first controlled-release base, and a second controlled-release base. The first controlled-release base is dissolved under an acidic condition. The second controlled-release base is dissolved under a weak acidic or a basic condition. 10-20wt% of the first controlled-release base is included to the swelling polymer. 10-40wt% of the second controlled-release base is included to the swelling polymer. The pharmacological acitivity component is selected from a group comprising pregabalin, gabapentine, metformin, ciprofloxacin, levodopa, trazodone, rebamipide, itopride, mosapride, teprenone, simvastatin, atorvastatin, pravastatin, pitavastatin, valsartan, losartan, candesartan, olmesartan, and azilsartan. [Reference numerals] (AA) Elution rate(%); (BB) Lyrica capsule 150mg; (CC) Example 2; (DD) Testing solution collecting time(minutes)
A system and device for obtaining and reviewing patient data and ultrasound images from a patient such that the patient data and ultrasound images can be viewed simultaneously. The ultrasound images are obtained by an ultrasound system in real-time during a procedure carried out on the patient. The physiology workstation receives patient data as well as the ultrasound images and stores both the patient data and the ultrasound images within the physiological recording system. The ultrasound images and patient data are also communicated to a central data storage device where the ultrasound images and patient data are stored and can be accessed by a remotely located reviewing station. A display contained on the physiology workstation allows both the ultrasound images and the patient data to be viewed at the physiology workstation. Preferably, the patient data and the ultrasound images include common, time -based synchronization data obtained from a synchronization signal such that the ultrasound images and patient data can be time-synchronized during subsequent viewing after the completion of the procedure.
This study tests the efficacy of a dyadic intervention to mitigate the adverse health consequences of SARS- CoV-2 (COVID-19) in African American (AA) adults with pre-existing chronic health conditions and their informal carepartners (IC). Socioeconomically disadvantaged, older, and Black/African American from rural regions are burdened with greater rates of chronic diseases such as diabetes, hypertension, chronic kidney disease, cardiovascular disease, and stroke. Those chronic diseases contribute to more severe health consequences and higher rates of mortality from COVID-19. POC are also more likely to be impacted by social and structural determinants of health (SSDH), such as barriers to health care access, discrimination, and lack of social support, that negatively impact quality of life (QoL) and effective chronic disease self- management behaviors. To provide the fullest health benefits to participants with chronic conditions in the wake of the COVID-19 pandemic, it is critical that we design interventions targeting SSDH for improved chronic disease self-management, health, functioning, QoL.

This study will utilize an embedded mixed methods design paired with an efficacy randomized controlled trial (RCT). Our iCINGS FAM (Integrating Community-based Intervention Under Nurse Guidance with Families) is a Registered Nurse (RN)-Community Health Worker (CHW)-delivered, telehealth intervention (14-weeks) that targets compounding racial- and pandemic-related stressors for improved chronic illness management and future disease risk mitigation in adult AA COVID-19 survivor/IC dyads.
Participants will complete 8 weekly therapy sessions focused on improving sleep. A multicomponent CBT-I (Cognitive Behavioral Therapy for Insomnia) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, and cognitive restructuring.
A microorganism strain  Lactobacillus plantarum  Inducia DSM 21379 for use as hypocholesterolemic, antimicrobial and anti-oxidative agent and as enhancer of the natural defense potential of a subject.  L. plantarum  Inducia is used for reducing the level of LDL-cholesterol in blood for preventing the cholesterol metabolism disorders and cardiovascular disorders.  L. plantarum  Inducia enhances simultaneously the natural defense potential and cellular immunity, and as anti-oxidative agent enhances anti-oxidative activity of blood by reducing the level of oxidized low density lipoprotein (ox-LDL). The strain is also used as an antimicrobial agent for lowering risk of  Clostridium difficile  associated diarrhoeae (CDAD) by preventing germination of  C. difficile  spores and by suppressing proliferation of its vegetative cells. The compositions comprising  L. plantarum  Inducia decrease the levels of LDL-cholesterol and ox-LDL in blood, enhance the natural defense potential and lower risk of CDAD. The composition may further comprise xylitol.
The degree of anaemia in sickle cell disease (SCD) is a well-known contributor to morbidity and mortality. We aimed to explore the factors affecting haemoglobin (Hb) level in African SCD patients, considering haemolysis biomarkers (LDH and bilirubin level, and reticulocyte count), leucocyte and platelet counts and socio-demographic characteristics (gender, age group, country of residence and BMI). The research was part of the CADRE multinational cohort and involved 3699 SCD patients living in Mali, Senegal, Ivory Coast, Democratic Republic of Congo, Gabon and Cameroon: 2936 SS/Sβ0, 587 SC and 176 Sβ + patients with median Hb level of 8, 11.3 and 11.2 g/dL respectively (p < 0.001). In multivariate analysis conducted in 1394 SS/Sβ0 patients, living in Cameroon, female gender, lower BMI, higher haemolysis markers (especially LDH) and higher leucocyte and platelet counts were independently associated with lower Hb level (all p < 0.05). In 497 SC and 156 Sβ + patients, female gender (p < 0.001), lower BMI (p < 0.05) and higher platelet counts (p < 0.001) were independently associated with lower Hb level. Anaemia in African SCD patients is not only associated with haemolysis but also with the country of residence, lower BMI and leucocyte or platelet counts which might reflect inflammation related to infectious burden in the region.
The patient received non-ablative fractional laser treatment once. Follow-up time: follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
To provide information regarding the effects of in utero exposure to primidone, physicians are advised to recommend that pregnant patients taking primidone enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.

The effects of primidone in human pregnancy and nursing infants are unknown.

Recent reports suggest an association between the use of anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in children born to these women. Data are more extensive with respect to diphenylhydantoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs.

The reports suggesting an elevated incidence of birth defects in children of drug-treated epileptic women cannot be regarded as adequate to prove a definite cause and effect relationship.

There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans; the possibility also exists that other factors leading to birth defects, e.g., genetic factors or the epileptic condition itself, may be more important than drug therapy. The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorders are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or fetus.

The prescribing physician will wish to weigh these considerations in treating or counseling epileptic women of childbearing potential. Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. Pregnant women under anticonvulsant therapy should receive prophylactic vitamin K1 therapy for one month prior to, and during, delivery.
This study examines the therapeutic effects of Shengmai Powder (SMP) on both in vitro and in vivo models of chronic obstructive pulmonary disease (COPD) and the underlying mechanisms. Cigarette smoke and cigarette extracts were used to create in vitro and in vivo models of COPD. ELISA was used to measure the levels of pro-inflammatory factors (IL-6, TNF-α, and IL-1β) in mouse lung tissue and alveolar macrophages. Flow cytometry assessed the phagocytic capacity of alveolar macrophage. Western blotting was used to analyze the expression of RhoA, PPARγ, IκBα, p-IκBα, P65, and p-P65 in alveolar. The results show that SMP reversed the increased levels of pro-inflammatory factors (IL-6, TNF-α, and IL-1β) in mouse lung tissue and alveolar macrophages induced by cigarette smoke and cigarette extract. SMP also restored the decreased fluorescence intensity and RhoA levels in alveolar macrophages caused by cigarette extract. Additionally, SMP increased PPARγ expression and decreased IκBα and P65 phosphorylation in alveolar macrophages exposed to cigarette extract. Also, the effects of SMP were reversed by PPARγ inhibitors. The study concluded that SMP regulates alveolar macrophage phagocytic function through the PPAR-γ/NF-κB pathway, thereby improving the chronic inflammatory state of COPD.
<P>PROBLEM TO BE SOLVED: To enable to harvest a large quantity of pharmaceuticals from sessile marine organisms.  <P>SOLUTION: The present invention relates to the culture of sessile marine organisms. Sessile marine organisms are a source of a large number of marine pharmaceuticals. A method for producing a marine pharmaceutical is provided. The method involves placing a plurality of substrate-like materials in sea water, growing the organism on the plurality of substrates, harvesting the grown organism on the plurality of substrates, subsequently extracting the pharmaceutical from the harvested organism.  <P>COPYRIGHT: (C)2010,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide a cosmetic with excellent UV protecting effect while having a characteristic as a concealer.  <P>SOLUTION: The invention relates to the oil gel cosmetic comprising (1) 3-10% by mass of polyethylene and (2) 10-25% by mass of silica-alumina coated titanium oxide. The cosmetic optionally contains 1-5% by mass of sintered particles of titanium dioxide and zinc oxide. A concealer or a pencil type cosmetic is preferred as the cosmetic. The cosmetic has ≥50 of SPF value (Sun Protection Factor), and obscures spots by covering and protects spots deteriorating by irradiation with UV light.  <P>COPYRIGHT: (C)2006,JPO&NCIPI